EUVIMEDObjevte EUVIMED
Randomisierte kontrollierte StudieOpen access

Impact of preventive pill‐based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention ( CHAMP ) trial and a comparison of self‐report to nosology‐derived assessments

Robert C Gibler iD, James L Peugh, Christopher S Coffey, Leigh Ann Chamberlin, Dixie Ecklund, Elizabeth Klingner, Jon Yankey, Leslie L Korbee, Marielle Kabbouche, Joanne Kacperski, Linda L Porter, Brooke L Reidy and 2 more

Headache: The Journal of Head and Face Pain · 2023

DOI: 10.1111/head.14474 ↗

At a glance

Randomisierte kontrollierte Studie in Headache: The Journal of Head and Face Pain, 2023. Written by Robert C Gibler and 13 co-authors. Institution: Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA. Major MEDLINE topics: Migraine Disorders, Headache Disorders. Cited 3 times so far (Crossref); 21 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, NINDS NIH HHS, National Institute of Child Health and Human Development.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Objective

To examine group differences in self‐reported migraine days among youth who completed the Childhood and Adolescent Migraine Prevention (CHAMP) trial prior to its closure and explore the relationship between self‐reported and “nosology‐derived” (i.e., International Classification of Headache Disorders, 3rd edition [ICHD‐3]) migraine days.

Background

The CHAMP trial compared amitriptyline and topiramate to placebo for migraine prevention in youth and proposed to analyze change in migraine days as a secondary outcome. There is considerable variability in the field regarding what constitutes a “migraine day,” how this is determined and reported in trials, and how consistent these measures are with diagnostic nosology.

Methods

CHAMP trial completers ( N = 175) were randomized to receive amitriptyline ( n = 77), topiramate ( n = 63), or placebo ( n = 35). Participants maintained daily headache diaries where they reported each day with headache and if they considered that headache to be a migraine. For each headache day, participants completed a symptom record and reported about symptoms such as pain location(s) and presence of nausea/vomiting or photophobia and phonophobia. We examined group differences in self‐reported migraine days at trial completion (summed from trial weeks 20–24) compared to baseline. We also used an algorithm to determine whether participants’ symptom reports met ICHD‐3 criteria for migraine without aura, and examined the association between self‐reported and “nosology‐derived” migraine days.

Results

Results showed no significant differences between groups in self‐reported migraine days over the course of the trial. Self‐reported and “nosology‐derived” migraine days during the baseline and treatment phases were strongly associated ( r 's = 0.73 and 0.83, respectively; p 's < 0.001).

Conclusion

Regardless of treatment, CHAMP trial completers showed clinically important reductions in self‐reported migraine days over the course of the trial (about 3.8 days less). The strong association between self‐reported and “nosology‐derived” migraine days suggests youth with migraine can recognize a day with migraine and reliably report their headache features and symptoms. Greater rigor and transparency in the calculation and reporting of migraine days in trials is needed.

Subjects

MeSH terms (MEDLINE)

Migraine DisordersHeadache DisordersHumansChildAdolescentTopiramateSelf ReportAmitriptylineFructoseOutcome Assessment, Health CareHeadacheTreatment OutcomeDouble-Blind Method

Author keywords

clinical trialmigrainemigraine daypediatricprevention

Substances

TopiramateAmitriptylineFructose

Authors and institutions

  • Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Headache Center, Cincinnati Children's Hospital Medical Center, Ohio, Cincinnati, USA.
  • Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Ohio, Cincinnati, USA.
  • Department of Biostatistics, University of Iowa, Iowa, Iowa City, USA.
  • Academic Regulatory & Monitoring Services, LLC, Cincinnati, Ohio, USA.
  • Division of Neurology, Cincinnati Children's Hospital Medical Center, Ohio, Cincinnati, USA.

ORCID profiles: Robert C Gibler, Andrew D Hershey, Scott W Powers

Funding

  • NIDDK NIH HHS
  • NINDS NIH HHS
  • National Institute of Child Health and Human Development
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Neurological Disorders and Stroke

Cite

APA

Gibler, R. C., Peugh, J. L., Coffey, C. S., Chamberlin, L. A., Ecklund, D., Klingner, E., Yankey, J., Korbee, L. L., Kabbouche, M., Kacperski, J., Porter, L. L., Reidy, B. L., Hershey, A. D., & Powers, S. W. (2023). Impact of preventive pill‐based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention ( CHAMP ) trial and a comparison of self‐report to nosology‐derived assessments. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14474

Vancouver

Gibler RC, Peugh JL, Coffey CS, Chamberlin LA, Ecklund D, Klingner E, et al. Impact of preventive pill‐based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention ( CHAMP ) trial and a comparison of self‐report to nosology‐derived assessments. Headache: The Journal of Head and Face Pain. 2023. doi:10.1111/head.14474

BibTeX
@article{Gibler2023,
  author = {Gibler, Robert C and Peugh, James L and Coffey, Christopher S and Chamberlin, Leigh Ann and Ecklund, Dixie and Klingner, Elizabeth and Yankey, Jon and Korbee, Leslie L and Kabbouche, Marielle and Kacperski, Joanne and Porter, Linda L and Reidy, Brooke L and Hershey, Andrew D and Powers, Scott W},
  title = {Impact of preventive pill‐based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention ( CHAMP ) trial and a comparison of self‐report to nosology‐derived assessments},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  doi = {10.1111/head.14474}
}
Start for free →